8 Amendments of Antonyia PARVANOVA related to 2011/2220(DEC)
Amendment 1 #
Proposal for a decision 1
Paragraph 1
Paragraph 1
1. ...Calls on the Agency to inform the discharge authority by the 30 June 2012 of the measures taken and of the improvements made in respect of all the areas of concern and decides to postpone the discharge to the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency's budget for the financial year 2010 ;
Amendment 20 #
Motion for a resolution
Paragraph 22 a (new)
Paragraph 22 a (new)
22 a. Calls the Agency to report on its involvement in the organization of conferences by private organizations such as the Organisation for Professionals in Regulatory Affairs (TOPRA) ;
Amendment 21 #
Motion for a resolution
Paragraph 23
Paragraph 23
23. Calls onUrges the Agency to provide the discharge authority with the guidelines and assessment criteria on handling potential conflicts of interest of staff members, experts and members of the Management Board;
Amendment 24 #
Motion for a resolution
Paragraph 24 a (new)
Paragraph 24 a (new)
24 a. Notes that the former Executive Director of the Agency wrote to the Agency on 28 December 2010 outlining the activities he was intending to take up at the end of his term of office; considers the first decision dated 11 January 2011 taken by the Chairman of the Agency Management Board to authorize the new activities of its former Executive Director a breach of Union rules relating to conflicts of interest, in particular with regard to Title II, Article 16 of the Staff Regulations of the Officials of the European Communities; recalls that according to Title II article 11 and title IV article 91 of Conditions of Employment of Other Servants of the European Communities, this disposal applies by analogy to temporary agents and to contract employees ; considers the fact that the Management Board adopted limitations on the future activities of the former Executive Director on 17 March 2011 - only after strong public protest - a clear proof that the Agency did initially not apply the Staff Regulations properly, which in turn raises serious questions about their application of the rules in general; asks the Executive Director of the Agency to present a detailed report of the implementation of Article 16 of the Staff Regulations within the Agency;
Amendment 28 #
Motion for a resolution
Paragraph 25 a (new)
Paragraph 25 a (new)
25 a. Regrets the fact that many of the experts failed to publish their declarations of interests (DoI), and that the comparison of DoI published by the relevant national agency and by the Agency shows significant differences in some cases; deplores, furthermore, the fact that at least one member of the Management Board of the Agency, also substitute member of the Committee for Medicinal Products for Human Use (CHMP), failed to declare his recent management responsibilities in a pharmaceutical firm ;
Amendment 30 #
Motion for a resolution
Paragraph 25 b (new)
Paragraph 25 b (new)
25 b. Urges the Agency to carry out checks on the declarations of interests submitted to it, and a detailed check on a random basis, notably in implementing a system under which declarations are cross-checked against information held by industry and by the relevant national agencies;
Amendment 32 #
Motion for a resolution
Paragraph 25 c (new)
Paragraph 25 c (new)
25 c. Urges the Agency to apply its conflict of interest policy to its Management Board ;
Amendment 34 #
Motion for a resolution
Paragraph 25 e (new)
Paragraph 25 e (new)
25 e. Considers that the effective management of conflict of interest is crucial to maintain public trust in the work of the Agency;